Talazoparib

TALAPRO-2

Talazoparib TALAPRO-2

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

PFS

ADJUSTMENTS

Quality of life

?

QoL data pending

Serious and disabling adverse effects

Other adjustments

Talazoparib TALAPRO-2

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

3

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: Talazoparib is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Experimental Arm: Talazoparib + Enzalutamide
Control Arm: Placebo plus enzalutamide

© 2024 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.